TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast

Purpose To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast. Patients and methods Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of endocrinological investigation 2018-11, Vol.41 (11), p.1301-1306
Hauptverfasser: Pirola, I., Gandossi, E., Brancato, D., Marini, F., Cristiano, A., Delbarba, A., Agosti, B., Castellano, M., Cappelli, C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1306
container_issue 11
container_start_page 1301
container_title Journal of endocrinological investigation
container_volume 41
creator Pirola, I.
Gandossi, E.
Brancato, D.
Marini, F.
Cristiano, A.
Delbarba, A.
Agosti, B.
Castellano, M.
Cappelli, C.
description Purpose To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast. Patients and methods Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter. Seven hundred ninety-eight patients were recruited and enrolled in the study. Thirty-seven subjects withdrew from the trial. A total of 761 patients (mean age 46.2 ± 10.8 years) completed the study. The starting dose of LT4 was determined through clinical judgment, taking into account TSH levels, estimated residual thyroid function, age, body weight and comorbidities. All patients underwent TSH, fT4, and fT3 evaluation to verify achievement of euthyroidism with their initial fasting state assumption of LT4 after 8 weeks of therapy. If euthyroidism was not achieved, an appropriately adjusted LT4 dose was administered for 8 weeks, after which thyroid function parameters were checked again. If euthyroidism was achieved, the patients were asked to take LT4 at breakfast and hormone levels were checked again after 6 months. Results At the end of the study period, no significant differences in serum TSH level were observed whether LT4 was ingested at breakfast or 30 min prior in a fasting state: 2.61 ± 1.79 vs. 2.54 ± 1.86 mIU/L, respectively ( p  = 0.455). Conclusions This study confirms in a large set of patients that a liquid LT4 formulation can be taken directly at breakfast and potentially improve therapeutic compliance.
doi_str_mv 10.1007/s40618-018-0867-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2019046956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2123083047</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2873-15d474ac5f460c5dc15e5ac5a125c9e4eaa783380e760600d9199b52853dd4f33</originalsourceid><addsrcrecordid>eNp1kctO3DAUhq0KVC7tA3RTWWLDJnB8i50lQoVBGolFp2vLk5zMhCbxYCeIeZs-C0-GR5lChdTFkS__d34f-SfkG4MLBqAvo4ScmQx2ZXKdiU_kmGkOmREmP_hnf0ROYnwAEFoY_Zkc8UIZLqQ8Jt3i54zik2tHNzS-p01P19uNH9bb4JuKbtIt9kOkLsaxa_oVbZvHMQktPk3Qc9MjdQNdBnS_axcH6gMV8PIn0XSJtQ_4rn0hh7VrI37dr6fk182PxfUsm9_f3l1fzbOSGy0ypiqppStVLXMoVVUyhSodHeOqLFCic9oIYQB1DjlAVbCiWCpulKgqWQtxSs4n303wjyPGwXZNLLFtXY9-jJYDK0DmhcoTevYBffBj6NN0ljMuwAiQOlFsosrgYwxY201oOhe2loHdZWGnLCzsKmVhd0N83zuPyw6rt46_n58APgExSf0Kw_vT_3d9BTxJlSk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2123083047</pqid></control><display><type>article</type><title>TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Pirola, I. ; Gandossi, E. ; Brancato, D. ; Marini, F. ; Cristiano, A. ; Delbarba, A. ; Agosti, B. ; Castellano, M. ; Cappelli, C.</creator><creatorcontrib>Pirola, I. ; Gandossi, E. ; Brancato, D. ; Marini, F. ; Cristiano, A. ; Delbarba, A. ; Agosti, B. ; Castellano, M. ; Cappelli, C.</creatorcontrib><description>Purpose To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast. Patients and methods Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter. Seven hundred ninety-eight patients were recruited and enrolled in the study. Thirty-seven subjects withdrew from the trial. A total of 761 patients (mean age 46.2 ± 10.8 years) completed the study. The starting dose of LT4 was determined through clinical judgment, taking into account TSH levels, estimated residual thyroid function, age, body weight and comorbidities. All patients underwent TSH, fT4, and fT3 evaluation to verify achievement of euthyroidism with their initial fasting state assumption of LT4 after 8 weeks of therapy. If euthyroidism was not achieved, an appropriately adjusted LT4 dose was administered for 8 weeks, after which thyroid function parameters were checked again. If euthyroidism was achieved, the patients were asked to take LT4 at breakfast and hormone levels were checked again after 6 months. Results At the end of the study period, no significant differences in serum TSH level were observed whether LT4 was ingested at breakfast or 30 min prior in a fasting state: 2.61 ± 1.79 vs. 2.54 ± 1.86 mIU/L, respectively ( p  = 0.455). Conclusions This study confirms in a large set of patients that a liquid LT4 formulation can be taken directly at breakfast and potentially improve therapeutic compliance.</description><identifier>ISSN: 1720-8386</identifier><identifier>ISSN: 0391-4097</identifier><identifier>EISSN: 1720-8386</identifier><identifier>DOI: 10.1007/s40618-018-0867-3</identifier><identifier>PMID: 29582344</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Body weight ; Breakfast ; Drug Administration Schedule ; Endocrinology ; Fasting ; Female ; Goiter ; Hormone Replacement Therapy ; Humans ; Hypothyroidism ; Hypothyroidism - blood ; Hypothyroidism - drug therapy ; Male ; Medicine ; Medicine &amp; Public Health ; Metabolic Diseases ; Middle Aged ; Original Article ; Thyroid ; Thyroid gland ; Thyroid-stimulating hormone ; Thyroidectomy ; Thyroiditis ; Thyrotropin - blood ; Thyroxine ; Thyroxine - administration &amp; dosage ; Thyroxine - therapeutic use ; Treatment Outcome</subject><ispartof>Journal of endocrinological investigation, 2018-11, Vol.41 (11), p.1301-1306</ispartof><rights>Italian Society of Endocrinology (SIE) 2018</rights><rights>Copyright Springer Science &amp; Business Media 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2873-15d474ac5f460c5dc15e5ac5a125c9e4eaa783380e760600d9199b52853dd4f33</citedby><cites>FETCH-LOGICAL-c2873-15d474ac5f460c5dc15e5ac5a125c9e4eaa783380e760600d9199b52853dd4f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40618-018-0867-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40618-018-0867-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29582344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pirola, I.</creatorcontrib><creatorcontrib>Gandossi, E.</creatorcontrib><creatorcontrib>Brancato, D.</creatorcontrib><creatorcontrib>Marini, F.</creatorcontrib><creatorcontrib>Cristiano, A.</creatorcontrib><creatorcontrib>Delbarba, A.</creatorcontrib><creatorcontrib>Agosti, B.</creatorcontrib><creatorcontrib>Castellano, M.</creatorcontrib><creatorcontrib>Cappelli, C.</creatorcontrib><title>TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast</title><title>Journal of endocrinological investigation</title><addtitle>J Endocrinol Invest</addtitle><addtitle>J Endocrinol Invest</addtitle><description>Purpose To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast. Patients and methods Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter. Seven hundred ninety-eight patients were recruited and enrolled in the study. Thirty-seven subjects withdrew from the trial. A total of 761 patients (mean age 46.2 ± 10.8 years) completed the study. The starting dose of LT4 was determined through clinical judgment, taking into account TSH levels, estimated residual thyroid function, age, body weight and comorbidities. All patients underwent TSH, fT4, and fT3 evaluation to verify achievement of euthyroidism with their initial fasting state assumption of LT4 after 8 weeks of therapy. If euthyroidism was not achieved, an appropriately adjusted LT4 dose was administered for 8 weeks, after which thyroid function parameters were checked again. If euthyroidism was achieved, the patients were asked to take LT4 at breakfast and hormone levels were checked again after 6 months. Results At the end of the study period, no significant differences in serum TSH level were observed whether LT4 was ingested at breakfast or 30 min prior in a fasting state: 2.61 ± 1.79 vs. 2.54 ± 1.86 mIU/L, respectively ( p  = 0.455). Conclusions This study confirms in a large set of patients that a liquid LT4 formulation can be taken directly at breakfast and potentially improve therapeutic compliance.</description><subject>Adult</subject><subject>Body weight</subject><subject>Breakfast</subject><subject>Drug Administration Schedule</subject><subject>Endocrinology</subject><subject>Fasting</subject><subject>Female</subject><subject>Goiter</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Hypothyroidism</subject><subject>Hypothyroidism - blood</subject><subject>Hypothyroidism - drug therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Thyroid</subject><subject>Thyroid gland</subject><subject>Thyroid-stimulating hormone</subject><subject>Thyroidectomy</subject><subject>Thyroiditis</subject><subject>Thyrotropin - blood</subject><subject>Thyroxine</subject><subject>Thyroxine - administration &amp; dosage</subject><subject>Thyroxine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1720-8386</issn><issn>0391-4097</issn><issn>1720-8386</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctO3DAUhq0KVC7tA3RTWWLDJnB8i50lQoVBGolFp2vLk5zMhCbxYCeIeZs-C0-GR5lChdTFkS__d34f-SfkG4MLBqAvo4ScmQx2ZXKdiU_kmGkOmREmP_hnf0ROYnwAEFoY_Zkc8UIZLqQ8Jt3i54zik2tHNzS-p01P19uNH9bb4JuKbtIt9kOkLsaxa_oVbZvHMQktPk3Qc9MjdQNdBnS_axcH6gMV8PIn0XSJtQ_4rn0hh7VrI37dr6fk182PxfUsm9_f3l1fzbOSGy0ypiqppStVLXMoVVUyhSodHeOqLFCic9oIYQB1DjlAVbCiWCpulKgqWQtxSs4n303wjyPGwXZNLLFtXY9-jJYDK0DmhcoTevYBffBj6NN0ljMuwAiQOlFsosrgYwxY201oOhe2loHdZWGnLCzsKmVhd0N83zuPyw6rt46_n58APgExSf0Kw_vT_3d9BTxJlSk</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Pirola, I.</creator><creator>Gandossi, E.</creator><creator>Brancato, D.</creator><creator>Marini, F.</creator><creator>Cristiano, A.</creator><creator>Delbarba, A.</creator><creator>Agosti, B.</creator><creator>Castellano, M.</creator><creator>Cappelli, C.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181101</creationdate><title>TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast</title><author>Pirola, I. ; Gandossi, E. ; Brancato, D. ; Marini, F. ; Cristiano, A. ; Delbarba, A. ; Agosti, B. ; Castellano, M. ; Cappelli, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2873-15d474ac5f460c5dc15e5ac5a125c9e4eaa783380e760600d9199b52853dd4f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Body weight</topic><topic>Breakfast</topic><topic>Drug Administration Schedule</topic><topic>Endocrinology</topic><topic>Fasting</topic><topic>Female</topic><topic>Goiter</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Hypothyroidism</topic><topic>Hypothyroidism - blood</topic><topic>Hypothyroidism - drug therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Thyroid</topic><topic>Thyroid gland</topic><topic>Thyroid-stimulating hormone</topic><topic>Thyroidectomy</topic><topic>Thyroiditis</topic><topic>Thyrotropin - blood</topic><topic>Thyroxine</topic><topic>Thyroxine - administration &amp; dosage</topic><topic>Thyroxine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pirola, I.</creatorcontrib><creatorcontrib>Gandossi, E.</creatorcontrib><creatorcontrib>Brancato, D.</creatorcontrib><creatorcontrib>Marini, F.</creatorcontrib><creatorcontrib>Cristiano, A.</creatorcontrib><creatorcontrib>Delbarba, A.</creatorcontrib><creatorcontrib>Agosti, B.</creatorcontrib><creatorcontrib>Castellano, M.</creatorcontrib><creatorcontrib>Cappelli, C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of endocrinological investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pirola, I.</au><au>Gandossi, E.</au><au>Brancato, D.</au><au>Marini, F.</au><au>Cristiano, A.</au><au>Delbarba, A.</au><au>Agosti, B.</au><au>Castellano, M.</au><au>Cappelli, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast</atitle><jtitle>Journal of endocrinological investigation</jtitle><stitle>J Endocrinol Invest</stitle><addtitle>J Endocrinol Invest</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>41</volume><issue>11</issue><spage>1301</spage><epage>1306</epage><pages>1301-1306</pages><issn>1720-8386</issn><issn>0391-4097</issn><eissn>1720-8386</eissn><abstract>Purpose To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast. Patients and methods Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter. Seven hundred ninety-eight patients were recruited and enrolled in the study. Thirty-seven subjects withdrew from the trial. A total of 761 patients (mean age 46.2 ± 10.8 years) completed the study. The starting dose of LT4 was determined through clinical judgment, taking into account TSH levels, estimated residual thyroid function, age, body weight and comorbidities. All patients underwent TSH, fT4, and fT3 evaluation to verify achievement of euthyroidism with their initial fasting state assumption of LT4 after 8 weeks of therapy. If euthyroidism was not achieved, an appropriately adjusted LT4 dose was administered for 8 weeks, after which thyroid function parameters were checked again. If euthyroidism was achieved, the patients were asked to take LT4 at breakfast and hormone levels were checked again after 6 months. Results At the end of the study period, no significant differences in serum TSH level were observed whether LT4 was ingested at breakfast or 30 min prior in a fasting state: 2.61 ± 1.79 vs. 2.54 ± 1.86 mIU/L, respectively ( p  = 0.455). Conclusions This study confirms in a large set of patients that a liquid LT4 formulation can be taken directly at breakfast and potentially improve therapeutic compliance.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>29582344</pmid><doi>10.1007/s40618-018-0867-3</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1720-8386
ispartof Journal of endocrinological investigation, 2018-11, Vol.41 (11), p.1301-1306
issn 1720-8386
0391-4097
1720-8386
language eng
recordid cdi_proquest_miscellaneous_2019046956
source MEDLINE; SpringerLink Journals
subjects Adult
Body weight
Breakfast
Drug Administration Schedule
Endocrinology
Fasting
Female
Goiter
Hormone Replacement Therapy
Humans
Hypothyroidism
Hypothyroidism - blood
Hypothyroidism - drug therapy
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Original Article
Thyroid
Thyroid gland
Thyroid-stimulating hormone
Thyroidectomy
Thyroiditis
Thyrotropin - blood
Thyroxine
Thyroxine - administration & dosage
Thyroxine - therapeutic use
Treatment Outcome
title TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A23%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TSH%20evaluation%20in%20hypothyroid%20patients%20assuming%20liquid%20levothyroxine%20at%20breakfast%20or%2030%C2%A0min%20before%20breakfast&rft.jtitle=Journal%20of%20endocrinological%20investigation&rft.au=Pirola,%20I.&rft.date=2018-11-01&rft.volume=41&rft.issue=11&rft.spage=1301&rft.epage=1306&rft.pages=1301-1306&rft.issn=1720-8386&rft.eissn=1720-8386&rft_id=info:doi/10.1007/s40618-018-0867-3&rft_dat=%3Cproquest_cross%3E2123083047%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2123083047&rft_id=info:pmid/29582344&rfr_iscdi=true